-+ 0.00%
-+ 0.00%
-+ 0.00%

4D Molecular Therapeutics Cuts Workforce By 25% In July 2025 To Save $15M Annually, Extend Cash Runway Into 2028

Benzinga·07/02/2025 20:22:35
Listen to the news
  • Implemented a workforce reduction of approximately 25% of current and planned roles in July 2025, primarily in the areas supporting early-stage research and development and support functions.
  • The workforce reduction is expected to provide annual cash compensation cost savings of approximately $15 million and offsets additional expenses expected based on the accelerated timelines for the 4FRONT clinical trials and BLA preparation, which supports the Company's cash runway into 2028, as previously guided.